Partner

Graziano Seghezzi is a Partner and he invests in life sciences. He joined the firm in 2006. 

Graziano invested in Creabilis Therapeutics (Italy), a specialty dermatology company developing products in multiple clinical areas such as psoriasis and atopic dermatitis; Crescendo Biologics (UK), a seed-stage company targeting the application of highly innovative antibody fragment technologies to the development of new therapeutics; GlycoVaxyn (Switzerland), a biotechnology company dedicated to the development of novel bacterial vaccines; Hookipa Biotech (Austria), a viral vaccines company; Mission Therapeutics (UK), an oncology company; and Omthera (USA), specialized in cardiovascular disorders with a best-in-class  omega-3 drug.  Graziano is a board member of each company.

Prior to joining Sofinnova Partners’ Paris-based team, Graziano was principal at Index Ventures in Geneva, Switzerland, where he invested in biotechnology and biopharmaceuticals companies.  Before this, he worked for Sofinnova Partners, identifying new investment opportunities in Italian pharmaceutical and medical device companies out of Milan, Italy. Graziano began his career as a biomedical researcher at New York University’s School of Medicine, where he gained five years of hands-on experience studying the molecular mechanism of angiogenesis in oncology and cardiovascular diseases.

Graziano has a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from the RSM, Erasmus University (Netherlands).